Company management will be presenting at the BMO Prescriptions for Success Healthcare Conference Date & Time: Thursday 14 December 2017 at…
Month: December 2017
ObsEva SA to Participate in BMO Healthcare Conference December 14th 2017
Geneva, Switzerland and Boston, MA _ December 7, 2017 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and…
ObsEva Initiates PROLONG, the Phase 2a Clinical Trial of OBE022 in Preterm Labor
OBE022 is a first-in-class, oral and selective PGF2alpha receptor antagonist for the potential treatment of preterm labor to delay or…
GnRH Receptor Antagonist Mono- And Combination Therapy With E2/NETA Add-Back – Pharmacodynamics And Safety Of OBE2109
Pohl O, Marchand L, Fawkes N, Gotteland JP, Loumaye E.